Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes
研究概览
详细说明
In diabetes management, compliance, disease awareness and empowerment of the patient play an important role and the immediate feedback on the effects of diet and exercise that the self monitoring blood glucose (SMBG) may provide, could enhance patient empowerment. Increased use of SMBG has been shown to be associated with improved medication compliance and better metabolic control by several studies. However, because of many factors, including pain and inconvenience, many diabetic patients do not accept frequent fingersticks for self blood glucose monitoring (SBGM) levels. In addition, the SBGM result gives the data for only a few seconds, without any information on glucose trends.
So we need new glucose monitoring method that could reflect glucose trends and glycemic excursion continuously because glucose monitoring still remains the cornerstone of evaluating the efficacy of therapy and motivating self disease control in subjects with diabetes.
Few studies have examined the effects of real time continuous glucose monitoring system targeting type 2 diabetes. So our goal is to determine whether the Guardian Continuous Glucose Monitoring System in the home setting is more useful than frequent self blood glucose monitoring with a view to modifying patient's diet and exercise habits or improvement self disease control efforts and at last glycemic control in patients with type 2 diabetes
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Seoul、大韩民国、152-703
- Division of Endocrinology and Metabolism, Department of Internal Medicine,Korea University College of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Type 2 diabetes
- Group 1: HbA1c < 8% with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months.
- Group 2: HbA1c >= 8% and the fasting blood glucose must be < 130 at the same time with a stable insulin or oral hypoglycemic agents (OHA) regimen for the prior 2 months with no plans to switch modality of insulin or OHA administration during the next 3months
Exclusion Criteria:
- Use of corticosteroids or hormone therapy within the last 6 months
- Presence of another chronic illness
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:乙
|
|
实验性的:A
Guardina RT monitoring
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
HbA1c, fasting blood glucose level, weight change, blood pressure in the morning, lipid profiles
大体时间:basline, 12weeks later
|
basline, 12weeks later
|
次要结果测量
结果测量 |
大体时间 |
---|---|
three day diary meals and seven day physical activity diary
大体时间:basline, 12 weeks later
|
basline, 12 weeks later
|
合作者和调查者
调查人员
- 首席研究员:Sei H Baik, MD、Division of Endocrinology and Metabolism, Department of Internal Medicine,Korea University College of Medicine
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
2型糖尿病的临床试验
-
Jin-Hee AhnAsan Medical Center未知HER-2基因扩增 | HER-2 蛋白过表达
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.未知
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.主动,不招人
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical Co...主动,不招人
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and Arts完全的
卫报的临床试验
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)完全的
-
University of Texas at AustinNational Heart, Lung, and Blood Institute (NHLBI)招聘中
-
Moai Technologies LLCSt. Louis University; University of Texas-Arlington招聘中